SONNET BIOTHERAPEUTICS HOLDI (SONN)

Company Profile

Sonnet Biotherapeutics Holdings Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Princeton, New Jersey and currently employs 12 full-time employees. The company went IPO on 2005-07-27. Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company. The firm's technology, namely Fully Human Albumin Binding (FHAB), utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The firm designed the FHAB construct to improve drug accumulation in cancer tumors, as well as to extend the duration of activity in the body. Its lead asset, SON-1010, is a fully human single-chain version of Interleukin 12 (IL-12), covalently linked to the FHAB construct, for which it is pursuing clinical development in solid tumors. Its lead clinical-stage asset, SON-080, is a fully human version of IL-6 manufactured in Chinese Hamster Ovary (CHO) cells. SON-080, for its target indications of Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN). Its pipeline also includes SON-1210, SON-1410 and SON-3015.

Company Info

SONNET BIOTHERAPEUTICS HOLDI

100 Overlook Center, Suite 102

Princeton NEW JERSEY 08540

P: 16093752227

CEO: Pankaj Mohan

Employees: 12

Website: https://www.sonnetbio.com/